AMEX:VNRX

VolitionRx Limited Schedules First Quarter 2018 Earnings Conference Call and Business Update

Conference call to take place Friday, May 11, 2018 at 8:30 am Eastern time ISNES, Belgium, May 4, 2018 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced it will host a conference call on Friday, May 11 at 8:30 a.m. Eastern time to discuss its financial and opera...

2018-05-04 20:00 1327

VolitionRx Announces Closing of $8.4 Million Public Offering of Common Stock

ISNES, Belgium, March 13, 2018 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN:  VNRX) ("Volition"), a multi-national life sciences company focused on developing simple, easy to use, cost effective blood tests designed to help diagnose a range of cancers, announced today the closing of its prev...

2018-03-14 04:05 502

VolitionRx Announces Pricing of $8.4 Million Public Offering of Common Stock

ISNES, Belgium, March 9, 2018 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national life sciences company focused on developing simple, easy to use, cost effective blood tests designed to help diagnose a range of cancers, announced today...

2018-03-09 22:10 867

VolitionRx Announces Proposed Underwritten Public Offering of Common Stock

NAMUR, Belgium, March 8, 2018 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national life sciences company focused on developing simple, easy to use, cost effective blood tests designed to help diagnose a range of cancers, announced t...

2018-03-09 05:01 573

VolitionRx Appoints Harvard Professor, Dr. Lee-Jen Wei to Its Scientific Advisory Board

ISNES, Belgium, March 7, 2018 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced that it has further strengthened its Scientific Advisory Board with the addition of Dr.Lee-Jen Wei, a professor of Biostatistics atHarvard University. Prof. Wei's main area of rese...

2018-03-07 21:30 627

VolitionRx Limited Schedules Full Year 2017 Earnings Conference Call and Business Update

Conference call to take place Friday, March 2, 2018 at 8:30 am Eastern time ISNES, Belgium, Feb. 28, 2018 /PRNewswire/ -- VolitionRx Limited (NYSE American:  VNRX) today announced it will host a conference call onFriday, March 2 at 8:30 a.m. Eastern time to discuss its financial and operating res...

2018-03-01 05:05 424

VolitionRx Limited Announces Interim Results from 680-Subject Clinical Trial in Colorectal Cancer

* Study demonstrates high detection rates of Stage I cancer and pre-cancerous adenomas in colorectal cancer screening trial for Nu.QTM blood test * Conference call to discuss interim results scheduled for Tuesday, February 27 at 8:30 a.m. Eastern Time ISNES, Belgium, Feb. 26, 2018 /PRNewswire/...

2018-02-27 05:05 432

VolitionRX Announces the Successful Conclusion of the Logistics and Pathway Design Study Conducted in Denmark.

ISNES, Belgium, Feb. 5, 2018 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced the successful conclusion to the Logistics and Pathway Design Study conducted by Hvidovre Hospital and The Danish Research Group.  The study was established to answer the very practi...

2018-02-05 21:30 498

VolitionRx Limited Releases Letter to Shareholders Including Status Update on Key Clinical Milestone

ISNES, Belgium, Jan. 3, 2018 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today released an important letter from Group CEO,Cameron Reynolds updating the company's shareholders. In the letter, Mr. Reynolds outlines several significant accomplishments to date and highligh...

2018-01-03 21:30 535

VolitionRx Limited to Attend Conferences in December

ISNES, Belgium, Dec. 5, 2017 /PRNewswire/ -- VolitionRx Limited  (NYSE American: VNRX) today announced that its Executive Vice President,Scott Powell, is scheduled to attend two conferences in December. During the conferences, management will outline Volition's busine...

2017-12-05 20:30 476

VolitionRx Limited Announces Third Quarter 2017 Financial Results and Business Update

ISNES, Belgium, Nov. 9, 2017 /PRNewswire/ -- VolitionRx Limited (NYSE American: VNRX) today announced financial results and a business update for the third quarter endedSeptember 30, 2017. Volition management will host a conference call tomorrow,November 10, at 8:30 a.m. U.S. Eastern Time to disc...

2017-11-10 05:05 660

VolitionRx Limited Schedules Third Quarter 2017 Earnings Conference Call and Business Update

Conference call to take place Friday, November 10, 2017 at 8:30 am Eastern time ISNES, Belgium, Nov. 2, 2017 /PRNewswire/ -- VolitionRx Limited (NYSE American:  VNRX) today announced it will host a conference call onFriday, November 10 at 8:30 a.m. Eastern time to discuss its financial and operat...

2017-11-02 20:30 443

VolitionRx Announces the Initial Sale of its New Nu.Q(TM) Research Kits

ISNES, Belgium, Sept. 22, 2017 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced its strategy for a new range of Clinical Research Use Only (RUO) kits based on its proprietary Nucleosomics™ technology and the receipt of an order of RUO kits from a large multin...

2017-09-22 20:30 3109

VolitionRx Announces its European Colorectal Cancer Strategy

ISNES, Belgium, Sept. 19, 2017 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced its colorectal cancer (CRC) strategy for Europe.  As part of its strategy, Volition plans to select a frontline panel to be validated in two large trials (4,300 and 10,000 sample),...

2017-09-20 04:30 1554

VolitionRx to Attend Two Major Conferences in Asia

ISNES, Belgium, Sept. 15, 2017 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced it will attend Asia Pacific Digestive Week (APDW) and will host a symposium at the Taiwan Digestive Disease Week (TDDW).  Volition's Vice President of Asia, Dr. Jasmine Kway, comm...

2017-09-15 19:30 1655

Volition Granted Four Additional Patents

ISNES, Belgium, Sept. 14, 2017 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced that it has been granted four additional patents relating to its proprietary Nu.QTM platform. The newly-issued patents further strengthen Volition's intellectual property portfoli...

2017-09-14 20:00 1268

VolitionRx Limited to Attend Multiple Conferences in September

ISNES, Belgium, Sept. 6, 2017 /PRNewswire/ -- VolitionRx Limited  (NYSE American: VNRX) today announced that its Chief Executive Officer,Cameron Reynolds, its Executive Vice President, Scott Powell, and/or its Chief Medical Officer, Dr. Jason Terrell, are scheduled t...

2017-09-07 04:30 1084

Volition Signs Agreement with the Institute of Laboratory Medicine of the Technical University of Munich, Germany, to assist in securing large trials in a range of cancers

ISNES, Belgium, Aug. 22, 2017 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) today announced a three-year agreement to work with the renowned expert ProfessorStefan Holdenrieder at the Institute of Laboratory Medicine of the German Heart Center at the Technical University ofMunich, G...

2017-08-23 04:30 1141

VolitionRx Limited Announces Second Quarter 2017 Financial Results and Business Update

ISNES, Belgium, Aug. 9, 2017 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced financial results and a business update for the quarter endedJune 30, 2017. Volition management will host a conference call to discuss these results and provide a further business up...

2017-08-10 04:05 1431

VolitionRx Limited Schedules Second Quarter 2017 Earnings Conference Call and Business Update

Conference call to take place Thursday, August 10, 2017 at 8:30 am Eastern time ISNES, Belgium, Aug. 3, 2017 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) today announced it will host a conference call onThursday, August 10, 2017 at 8:30 am Eastern time to discuss its financial and ope...

2017-08-04 04:30 3149